DE69433091D1 - Verwendung von an Glycoprotein gpIIb/IIIa bindenden Substanzen zur Vermeidung von Stenosis und Restenosis - Google Patents

Verwendung von an Glycoprotein gpIIb/IIIa bindenden Substanzen zur Vermeidung von Stenosis und Restenosis

Info

Publication number
DE69433091D1
DE69433091D1 DE69433091T DE69433091T DE69433091D1 DE 69433091 D1 DE69433091 D1 DE 69433091D1 DE 69433091 T DE69433091 T DE 69433091T DE 69433091 T DE69433091 T DE 69433091T DE 69433091 D1 DE69433091 D1 DE 69433091D1
Authority
DE
Germany
Prior art keywords
restenosis
immunoglobulins
binding substances
stenosis
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433091T
Other languages
English (en)
Other versions
DE69433091T2 (de
DE69433091T3 (de
Inventor
Barry S Coller
Harlan F Weisman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Janssen Biotech Inc
Original Assignee
Research Foundation of State University of New York
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22523494&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69433091(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Foundation of State University of New York, Centocor Inc filed Critical Research Foundation of State University of New York
Application granted granted Critical
Publication of DE69433091D1 publication Critical patent/DE69433091D1/de
Publication of DE69433091T2 publication Critical patent/DE69433091T2/de
Publication of DE69433091T3 publication Critical patent/DE69433091T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69433091T 1993-11-05 1994-11-07 Verwendung von an Glycoprotein gpIIb/IIIa bindenden Substanzen zur Vermeidung von Stenosis und Restenosis Expired - Lifetime DE69433091T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14792893A 1993-11-05 1993-11-05
US147928 1993-11-05
PCT/US1994/012779 WO1995012412A1 (en) 1993-11-05 1994-11-07 Platelet-specific chimeric immunoglobulin and methods of use therefor

Publications (3)

Publication Number Publication Date
DE69433091D1 true DE69433091D1 (de) 2003-10-02
DE69433091T2 DE69433091T2 (de) 2004-06-03
DE69433091T3 DE69433091T3 (de) 2009-07-30

Family

ID=22523494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433091T Expired - Lifetime DE69433091T3 (de) 1993-11-05 1994-11-07 Verwendung von an Glycoprotein gpIIb/IIIa bindenden Substanzen zur Vermeidung von Stenosis und Restenosis

Country Status (15)

Country Link
EP (2) EP1334730A3 (de)
JP (1) JPH09504795A (de)
CN (2) CN1140295C (de)
AT (1) ATE247980T1 (de)
AU (2) AU1172495A (de)
CA (1) CA2175214A1 (de)
DE (1) DE69433091T3 (de)
DK (1) DK0725655T4 (de)
ES (1) ES2204937T5 (de)
HK (1) HK1054682B (de)
NZ (2) NZ502819A (de)
PT (1) PT725655E (de)
RU (1) RU2158135C2 (de)
UA (1) UA37249C2 (de)
WO (1) WO1995012412A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5753230A (en) † 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1996040250A2 (en) * 1995-06-07 1996-12-19 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
CA2282501A1 (en) * 1997-02-19 1998-08-27 Centocor, Inc. Sustained drug delivery and compositions useful therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1297815C (en) * 1985-06-07 1992-03-24 Barry S. Coller Fibrinogen blocking monoclonal antibody
CA1297816C (en) * 1985-06-14 1992-03-24 Barry S. Coller Platelet function inhibiting monoclonal antibody fragment
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
ATE124267T1 (de) * 1989-04-03 1995-07-15 Centocor Inc Blutplättchenspezifische immunokonjugate.
EP0606391B1 (de) * 1991-09-30 1998-08-05 Biogen, Inc. Hemmung von Gefässverengung unter Verwendung von anti-PADGEM Antikörpern.
WO1993013133A1 (en) * 1991-12-20 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa

Also Published As

Publication number Publication date
AU8959398A (en) 1999-01-14
HK1054682B (zh) 2006-05-04
DE69433091T2 (de) 2004-06-03
CN1230201C (zh) 2005-12-07
PT725655E (pt) 2004-01-30
WO1995012412A1 (en) 1995-05-11
EP1334730A3 (de) 2003-12-03
ES2204937T5 (es) 2009-07-06
CA2175214A1 (en) 1995-05-11
CN1140295C (zh) 2004-03-03
DE69433091T3 (de) 2009-07-30
RU2158135C2 (ru) 2000-10-27
EP1334730A2 (de) 2003-08-13
JPH09504795A (ja) 1997-05-13
DK0725655T4 (da) 2009-05-18
AU1172495A (en) 1995-05-23
NZ502819A (en) 2002-09-27
EP0725655B1 (de) 2003-08-27
EP0725655A1 (de) 1996-08-14
EP0725655B2 (de) 2009-04-15
UA37249C2 (uk) 2001-05-15
CN1142189A (zh) 1997-02-05
ATE247980T1 (de) 2003-09-15
HK1054682A1 (en) 2003-12-12
DK0725655T3 (da) 2004-01-05
CN1404877A (zh) 2003-03-26
ES2204937T3 (es) 2004-05-01
NZ527820A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
DE10299038I2 (de) Pl{ttchen-spezifisches Chim{risches immunglobulin.
EP0371998A4 (en) Modular assembly of antibody genes, antibodies prepared thereby and use
ATE268818T1 (de) Ctla4-mutantmoleküle und deren verwendung
DE58909458D1 (de) Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung.
ATE151113T1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
ATE168013T1 (de) Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung
AU1042192A (en) Recombinant antibodies specific for a growth factor receptor
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
DE69433091D1 (de) Verwendung von an Glycoprotein gpIIb/IIIa bindenden Substanzen zur Vermeidung von Stenosis und Restenosis
DE69624259T2 (de) Vaskulare endothelzelle-wachstumsfaktor antiidotypische antikörper und ihre verwendung als arzneimittel
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
WO1996040250A3 (en) Platelet-specific chimeric immunoglobulin and methods of use therefor
Wines et al. The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings